Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1991 4
1992 1
1993 1
1995 2
1997 2
1999 2
2000 3
2002 2
2003 7
2004 8
2005 6
2006 3
2007 10
2008 2
2009 7
2010 14
2011 14
2012 27
2013 18
2014 21
2015 31
2016 46
2017 37
2018 41
2019 44
2020 73
2021 91
2022 85
2023 91
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

636 results

Results by year

Filters applied: . Clear all
Page 1
LC-MS/MS quantitation of non-psychotropic cannabinoid cannabidiol in aqueous humor.
Aebersold AS, Kumar A, Song ZH. Aebersold AS, et al. J Pharm Biomed Anal. 2023 May 10;228:115324. doi: 10.1016/j.jpba.2023.115324. Epub 2023 Mar 5. J Pharm Biomed Anal. 2023. PMID: 36907022
Cannabidiol (CBD) is the most abundant non-psychotropic phytocannabinoid isolated from Cannabis sativa. ...The AUC was 183.4 49.17 ng * h/mL. The development and validation of this LC-MS/MS method is an important step toward the goal of assessing the aqueous
Cannabidiol (CBD) is the most abundant non-psychotropic phytocannabinoid isolated from Cannabis sativa. ...The AUC was 183.4 49.17 ng
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.
O'Brien TJ, Berkovic SF, French JA, Messenheimer JA, Sebree TB, Bonn-Miller MO, Gutterman DL; STAR 1/STAR 2 Study Group. O'Brien TJ, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2220189. doi: 10.1001/jamanetworkopen.2022.20189. JAMA Netw Open. 2022. PMID: 35802375 Free PMC article. Clinical Trial.
RESULTS: A total of 188 patients (45% male [85 patients] and 54.8% female [103 patients]) with a mean (SD) age of 39.2 (12.78) years were randomized, treated, and analyzed (195-mg cannabidiol, 63 participants; 390-mg cannabidiol, 62 participants; placebo, 63 partici …
RESULTS: A total of 188 patients (45% male [85 patients] and 54.8% female [103 patients]) with a mean (SD) age of 39.2 (12.78) years were ra …
Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.
Balachandran P, Elsohly M, Hill KP. Balachandran P, et al. J Gen Intern Med. 2021 Jul;36(7):2074-2084. doi: 10.1007/s11606-020-06504-8. Epub 2021 Jan 29. J Gen Intern Med. 2021. PMID: 33515191 Free PMC article. Review.
Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. ...
Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. ...
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis.
Pichini S, Malaca S, Gottardi M, Pérez-Acevedo AP, Papaseit E, Perez-Maña C, Farré M, Pacifici R, Tagliabracci A, Mannocchi G, Busardò FP. Pichini S, et al. Talanta. 2021 Feb 1;223(Pt 2):121772. doi: 10.1016/j.talanta.2020.121772. Epub 2020 Oct 14. Talanta. 2021. PMID: 33298281
We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) for quantifying cannabidiol (CBD) and its metabolites, cannabidiol-7-oic acid (7-COOH-CBD), 7- hydroxycannabidiol …
We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS
UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations.
Malaca S, Gottardi M, Pigliasco F, Barco S, Cafaro A, Amadori E, Riva A, Marcenaro M, Striano P, Cangemi G, Pacifici R, Pichini S, Busardò FP. Malaca S, et al. Pharmaceuticals (Basel). 2021 Jun 29;14(7):630. doi: 10.3390/ph14070630. Pharmaceuticals (Basel). 2021. PMID: 34209666 Free PMC article.
Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. ...We herein report for the first time a newly developed and validated method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometr
Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. ...We herein report for t
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E. Solmi M, et al. BMJ. 2023 Aug 30;382:e072348. doi: 10.1136/bmj-2022-072348. BMJ. 2023. PMID: 37648266 Free PMC article. Review.
For chronic pain, cannabis based medicines or cannabinoids reduced pain by 30% (0.59 (0.37 to 0.93), GRADE=high), across different conditions (n=7), but increased psychological distress. For epilepsy, cannabidiol increased risk of diarrhoea (2.25 (1.33 to 3.81)), had no ef …
For chronic pain, cannabis based medicines or cannabinoids reduced pain by 30% (0.59 (0.37 to 0.93), GRADE=high), across different condition …
LC-MS/MS Assay for the Measurement of Cannabidiol Profiling in CBD Oil from Japanese Market and Application for Convertible Tetrahydrocannabinol in Acetic Acid Condition.
Takashina S, Takahashi M, Morimoto K, Inoue K. Takashina S, et al. Chem Pharm Bull (Tokyo). 2022;70(2):169-174. doi: 10.1248/cpb.c21-00901. Chem Pharm Bull (Tokyo). 2022. PMID: 35110438 Free article.
In this study, a routine assay for evaluating CBD oil samples was performed using LC coupled with tandem mass spectrometry (LC-MS/MS) and was used to apply the convertible tetrahydrocannabinol (THC) in acetic acid conditions. ...Following that, we investigated the c …
In this study, a routine assay for evaluating CBD oil samples was performed using LC coupled with tandem mass spectrometry (LC-MS/ …
Development of an UHPLC-MS/MS method to determine cutaneous biodistribution of cannabidiol after topical application of cannabidiol gel assisted by iontophoresis.
Kang D, Wang C, Liu W, Yang M, Cheng X, Chen Y. Kang D, et al. Biomed Chromatogr. 2023 Nov;37(11):e5735. doi: 10.1002/bmc.5735. Epub 2023 Aug 31. Biomed Chromatogr. 2023. PMID: 37651752
However, currently existing quantification methods for the investigation of cannabidiol skin distribution are not optimal. This study aimed to establish a method for the determination of cannabidiol in skin samples by UHPLC-MS/MS. ...The intra-day and …
However, currently existing quantification methods for the investigation of cannabidiol skin distribution are not optimal. This study …
Cannabidiol and Other Cannabinoids in Demyelinating Diseases.
Navarrete C, García-Martín A, Rolland A, DeMesa J, Muñoz E. Navarrete C, et al. Int J Mol Sci. 2021 Mar 15;22(6):2992. doi: 10.3390/ijms22062992. Int J Mol Sci. 2021. PMID: 33804243 Free PMC article. Review.
A growing body of preclinical evidence indicates that certain cannabinoids, including cannabidiol (CBD) and synthetic derivatives, may play a role in the myelinating processes and are promising small molecules to be developed as drug candidates for management of demyelinat …
A growing body of preclinical evidence indicates that certain cannabinoids, including cannabidiol (CBD) and synthetic derivatives, ma …
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.
Maccarrone M, Di Marzo V, Gertsch J, Grether U, Howlett AC, Hua T, Makriyannis A, Piomelli D, Ueda N, van der Stelt M. Maccarrone M, et al. Pharmacol Rev. 2023 Sep;75(5):885-958. doi: 10.1124/pharmrev.122.000600. Epub 2023 May 10. Pharmacol Rev. 2023. PMID: 37164640 Review.
Compelling research evidence and the Food and Drug Administration cannabis-derived cannabidiol approval for severe childhood epilepsy have confirmed the large therapeutic potential of cannabidiol itself, delta(9)-tetrahydrocannabinol and other plant-derived cannabin …
Compelling research evidence and the Food and Drug Administration cannabis-derived cannabidiol approval for severe childhood epilepsy …
636 results